Cargando…

Is Good Clinical Practice Becoming Poor Clinical Care?

Detalles Bibliográficos
Autores principales:	Le Gouill, Steven, Dreyling, Martin, Caballero, Maria Dolores, Andre, Marc, Doorduijn, Jeannette, Jurczak, Wojciech, Jerkeman, Mats, Ghia, Paolo, Zinzani, Pier-Luigi, Da Silva, Maria Gomez, Dimopoulos, Meletios, Trneny, Marek, Delarue, Richard, Walewski, Jan, Gisselbrecht, Christian, López-Guillermo, Armando, Rule, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745974/ https://www.ncbi.nlm.nih.gov/pubmed/31723733 http://dx.doi.org/10.1097/HS9.0000000000000004

Ejemplares similares

Reducing Bureaucracy in Clinical Research: A Call for Action
por: Gribben, John, et al.
Publicado: (2020)

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
por: Rule, S, et al.
Publicado: (2018)

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
por: Sureda, Anna, et al.
Publicado: (2020)

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic
por: Dreyling, Martin, et al.
Publicado: (2021)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

New Treatment Options in Advanced Stage Follicular Lymphoma
por: Hübel, Kai, et al.
Publicado: (2018)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB
por: Le Gouill, S., et al.
Publicado: (2022)

JRCPL Becomes Clinical Medicine
Publicado: (2000)

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
por: Scheubeck, Gabriel, et al.
Publicado: (2023)

Andrologie becomes Basic and Clinical Andrology
por: Mieusset, Roger
Publicado: (2013)

Expanded clinical and experimental use of SOX11 - using a monoclonal antibody
por: Nordström, Lena, et al.
Publicado: (2012)

How to become a good surgeon
por: Wiedemann, Peter
Publicado: (2023)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
por: Alexopoulos, Harry, et al.
Publicado: (2023)

Face Transplantation: On the Verge of Becoming Clinical Routine?
por: Smeets, Ralf, et al.
Publicado: (2014)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

When falls become fatal—Clinical care sequence
por: Drake, Stacy A., et al.
Publicado: (2021)

The path to becoming a clinical or radiation oncologist in Nigeria
por: Onyeodi, Ifeanyichukwu Augustine, et al.
Publicado: (2022)

Stalking in clinical psychiatry: when the doctor becomes the victim
por: Signori, João Pedro Soledade, et al.
Publicado: (2022)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

The extended 4-year follow-up results of the ELOQUENT-2 trial
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review
por: Fiste, Oraianthi, et al.
Publicado: (2020)

Requirements for a lead compound to become a clinical candidate
por: Hefti, Franz F
Publicado: (2008)

Are clinical genomes already becoming semi-routine for patient care?
por: Boguski, Mark
Publicado: (2011)

Paul Emmelkamp Becomes “Ambassador of Clinical Psychology and Psychological Treatment”
por: Nauta, Maaike H., et al.
Publicado: (2022)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer
por: Olofsson, Sven-Erik, et al.
Publicado: (2015)

Clinical Characteristics and Histopathological Patterns of Hodgkin Lymphoma and Treatment Outcomes at a Tertiary Cancer Center in Ethiopia
por: Adam, Makka, et al.
Publicado: (2021)

Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
por: Hohloch, Karin, et al.
Publicado: (2020)

Lysophosphatidic acid, LPA: a bad boy becomes good
por: Budnik, Lygia T
Publicado: (2003)

When Intensive Care Becomes Good End-of-Life Care
por: Wunsch, Hannah
Publicado: (2020)

Becoming a Physician Who is a Good Communicator to Patients
por: Hu, Xiaojing
Publicado: (2023)

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
por: Jiang, Yichuan, et al.
Publicado: (2023)

EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas
por: Ladetto, Marco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p6ud14cgl62s5rm7ins19fflq0